Survey NEN / Inquérito NEN
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Brazilian Journal of Health Review |
Texto Completo: | https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/49858 |
Resumo: | Introduction: Although new treatments and diagnostic methods for Neuroendocrine Neoplasms (NEN) have been introduced, the level of access to them needs somehow to be further investigated. Objectives: to understand the aspects that influence the access to the diagnosis, follow-up and treatment of patients with NEN in Brazil. Methods: This is a cross-sectional electronic survey conducted by the Brazilian Group of Gastrointestinal Tumors (GTG) and containing sixteen questions sent to Brazilian Oncologists via messaging app, aiming to identify access profiles to diagnostic and follow-up tests among patients with NEN, in addition to proven effective treatments in the Public and Private Brazilian Health Care System. Descriptive analysis was used to report the outcomes.Results: The survey was carried out with 201 Oncologists. Since (31.8%) of the Oncologists responded that they have been trained for more than 15 years and have been working with clinical practice within the scope of the Brazilian National Health System and/or the Private Health Care. For follow-up, the most requested marker was Chromogranin A (39%). Regarding diagnosis, 35.8% of the 201 participants claim to ask for a slide review in their clinical practice, and their access to tomography and resonance (58%). When contextualizing the performance of PET Scan with Gallium 68, it is available in (15%), but a significant percentage did not have access in the Brazilian National Health System Service, corresponding to (95%). Subgroup analysis revealed statistically significant differences in the availability of Somatostatin Analogue, being offered in 56% in the Brazilian National Health System and 84% in the Private Health Care (p < 0.05). Conclusion: This is the first Brazilian research that evaluated access to diagnostic and therapeutic tools in the Brazilian scenario, showing important access limitations, especially in the public sector. In view of the results presented, these restrictions can lead to unfavorable clinical outcomes in patients with NEN in Brazil. |
id |
BJRH-0_57c2ce4f506f2b80e6973c423dd35bb9 |
---|---|
oai_identifier_str |
oai:ojs2.ojs.brazilianjournals.com.br:article/49858 |
network_acronym_str |
BJRH-0 |
network_name_str |
Brazilian Journal of Health Review |
repository_id_str |
|
spelling |
Survey NEN / Inquérito NENNeuroendocrine Carcinomaantineoplasticssurveys and questionnaireshealth system.Introduction: Although new treatments and diagnostic methods for Neuroendocrine Neoplasms (NEN) have been introduced, the level of access to them needs somehow to be further investigated. Objectives: to understand the aspects that influence the access to the diagnosis, follow-up and treatment of patients with NEN in Brazil. Methods: This is a cross-sectional electronic survey conducted by the Brazilian Group of Gastrointestinal Tumors (GTG) and containing sixteen questions sent to Brazilian Oncologists via messaging app, aiming to identify access profiles to diagnostic and follow-up tests among patients with NEN, in addition to proven effective treatments in the Public and Private Brazilian Health Care System. Descriptive analysis was used to report the outcomes.Results: The survey was carried out with 201 Oncologists. Since (31.8%) of the Oncologists responded that they have been trained for more than 15 years and have been working with clinical practice within the scope of the Brazilian National Health System and/or the Private Health Care. For follow-up, the most requested marker was Chromogranin A (39%). Regarding diagnosis, 35.8% of the 201 participants claim to ask for a slide review in their clinical practice, and their access to tomography and resonance (58%). When contextualizing the performance of PET Scan with Gallium 68, it is available in (15%), but a significant percentage did not have access in the Brazilian National Health System Service, corresponding to (95%). Subgroup analysis revealed statistically significant differences in the availability of Somatostatin Analogue, being offered in 56% in the Brazilian National Health System and 84% in the Private Health Care (p < 0.05). Conclusion: This is the first Brazilian research that evaluated access to diagnostic and therapeutic tools in the Brazilian scenario, showing important access limitations, especially in the public sector. In view of the results presented, these restrictions can lead to unfavorable clinical outcomes in patients with NEN in Brazil.Brazilian Journals Publicações de Periódicos e Editora Ltda.2022-07-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/4985810.34119/bjhrv5n4-008Brazilian Journal of Health Review; Vol. 5 No. 4 (2022); 12017-12029Brazilian Journal of Health Review; v. 5 n. 4 (2022); 12017-120292595-6825reponame:Brazilian Journal of Health Reviewinstname:Federação das Indústrias do Estado do Paraná (FIEP)instacron:BJRHporhttps://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/49858/pdfCopyright (c) 2022 Brazilian Journal of Health Reviewinfo:eu-repo/semantics/openAccessLima, Carla Andressa Rodrigues Dias Fleury dePeixoto, Renata D'AlpinoWeschenfelder, Rui F.Prolla, GabrielRego, Juliana FRocha, DuilioCrosara, MarcelaFernandes, GustavoHoff, Paulo MAndrade, Aline ChavesCoutinho, Anelisa K.Riechelmann, Rachel P.2022-08-31T17:59:44Zoai:ojs2.ojs.brazilianjournals.com.br:article/49858Revistahttp://www.brazilianjournals.com/index.php/BJHR/indexPRIhttps://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/oai|| brazilianjhr@gmail.com2595-68252595-6825opendoar:2022-08-31T17:59:44Brazilian Journal of Health Review - Federação das Indústrias do Estado do Paraná (FIEP)false |
dc.title.none.fl_str_mv |
Survey NEN / Inquérito NEN |
title |
Survey NEN / Inquérito NEN |
spellingShingle |
Survey NEN / Inquérito NEN Lima, Carla Andressa Rodrigues Dias Fleury de Neuroendocrine Carcinoma antineoplastics surveys and questionnaires health system. |
title_short |
Survey NEN / Inquérito NEN |
title_full |
Survey NEN / Inquérito NEN |
title_fullStr |
Survey NEN / Inquérito NEN |
title_full_unstemmed |
Survey NEN / Inquérito NEN |
title_sort |
Survey NEN / Inquérito NEN |
author |
Lima, Carla Andressa Rodrigues Dias Fleury de |
author_facet |
Lima, Carla Andressa Rodrigues Dias Fleury de Peixoto, Renata D'Alpino Weschenfelder, Rui F. Prolla, Gabriel Rego, Juliana F Rocha, Duilio Crosara, Marcela Fernandes, Gustavo Hoff, Paulo M Andrade, Aline Chaves Coutinho, Anelisa K. Riechelmann, Rachel P. |
author_role |
author |
author2 |
Peixoto, Renata D'Alpino Weschenfelder, Rui F. Prolla, Gabriel Rego, Juliana F Rocha, Duilio Crosara, Marcela Fernandes, Gustavo Hoff, Paulo M Andrade, Aline Chaves Coutinho, Anelisa K. Riechelmann, Rachel P. |
author2_role |
author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Lima, Carla Andressa Rodrigues Dias Fleury de Peixoto, Renata D'Alpino Weschenfelder, Rui F. Prolla, Gabriel Rego, Juliana F Rocha, Duilio Crosara, Marcela Fernandes, Gustavo Hoff, Paulo M Andrade, Aline Chaves Coutinho, Anelisa K. Riechelmann, Rachel P. |
dc.subject.por.fl_str_mv |
Neuroendocrine Carcinoma antineoplastics surveys and questionnaires health system. |
topic |
Neuroendocrine Carcinoma antineoplastics surveys and questionnaires health system. |
description |
Introduction: Although new treatments and diagnostic methods for Neuroendocrine Neoplasms (NEN) have been introduced, the level of access to them needs somehow to be further investigated. Objectives: to understand the aspects that influence the access to the diagnosis, follow-up and treatment of patients with NEN in Brazil. Methods: This is a cross-sectional electronic survey conducted by the Brazilian Group of Gastrointestinal Tumors (GTG) and containing sixteen questions sent to Brazilian Oncologists via messaging app, aiming to identify access profiles to diagnostic and follow-up tests among patients with NEN, in addition to proven effective treatments in the Public and Private Brazilian Health Care System. Descriptive analysis was used to report the outcomes.Results: The survey was carried out with 201 Oncologists. Since (31.8%) of the Oncologists responded that they have been trained for more than 15 years and have been working with clinical practice within the scope of the Brazilian National Health System and/or the Private Health Care. For follow-up, the most requested marker was Chromogranin A (39%). Regarding diagnosis, 35.8% of the 201 participants claim to ask for a slide review in their clinical practice, and their access to tomography and resonance (58%). When contextualizing the performance of PET Scan with Gallium 68, it is available in (15%), but a significant percentage did not have access in the Brazilian National Health System Service, corresponding to (95%). Subgroup analysis revealed statistically significant differences in the availability of Somatostatin Analogue, being offered in 56% in the Brazilian National Health System and 84% in the Private Health Care (p < 0.05). Conclusion: This is the first Brazilian research that evaluated access to diagnostic and therapeutic tools in the Brazilian scenario, showing important access limitations, especially in the public sector. In view of the results presented, these restrictions can lead to unfavorable clinical outcomes in patients with NEN in Brazil. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-07-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/49858 10.34119/bjhrv5n4-008 |
url |
https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/49858 |
identifier_str_mv |
10.34119/bjhrv5n4-008 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/49858/pdf |
dc.rights.driver.fl_str_mv |
Copyright (c) 2022 Brazilian Journal of Health Review info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2022 Brazilian Journal of Health Review |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Brazilian Journals Publicações de Periódicos e Editora Ltda. |
publisher.none.fl_str_mv |
Brazilian Journals Publicações de Periódicos e Editora Ltda. |
dc.source.none.fl_str_mv |
Brazilian Journal of Health Review; Vol. 5 No. 4 (2022); 12017-12029 Brazilian Journal of Health Review; v. 5 n. 4 (2022); 12017-12029 2595-6825 reponame:Brazilian Journal of Health Review instname:Federação das Indústrias do Estado do Paraná (FIEP) instacron:BJRH |
instname_str |
Federação das Indústrias do Estado do Paraná (FIEP) |
instacron_str |
BJRH |
institution |
BJRH |
reponame_str |
Brazilian Journal of Health Review |
collection |
Brazilian Journal of Health Review |
repository.name.fl_str_mv |
Brazilian Journal of Health Review - Federação das Indústrias do Estado do Paraná (FIEP) |
repository.mail.fl_str_mv |
|| brazilianjhr@gmail.com |
_version_ |
1797240076204244992 |